Mark E Haskins1. 1. Departments of Pathobiology and Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104-6051, USA. mhaskins@vet.upenn.edu
Abstract
UNLABELLED: Progress in understanding how a particular genotype produces the phenotype of an inborn error of metabolism, such as a mucopolysaccharidosis, in human patients has been facilitated by the study of animals with mutations in the orthologous genes. These are not just animal models, but true orthologues of the human genetic disease, with defects involving the same evolutionarily conserved genes and the same molecular, biochemical, and anatomic lesions as in human patients. These animals are often domestic species because of the individual medical attention paid to them, particularly dogs and cats. In addition, naturally occurring mouse models have also been found in breeding colonies. Within the last several decades, advances in molecular biology have allowed the production of knockout mouse models of human genetic disease, including the lysosomal storage diseases. The ability to use both inbred strains of a small, prolific species together with larger out-bred animals found because of their disease phenotype provides a powerful combination with which to investigate pathogenesis, develop approaches to therapy, and define biomarkers to evaluate therapeutic success. This has been true for the inborn errors of metabolism and, in particular, the mucopolysaccharidoses. CONCLUSION: Animal models of human genetic disease continue to play an important role in understanding the molecular and physiological consequences of lysosomal storage diseases and to provide an opportunity to evaluate the efficacy and safety of therapeutic interventions.
UNLABELLED: Progress in understanding how a particular genotype produces the phenotype of an inborn error of metabolism, such as a mucopolysaccharidosis, in humanpatients has been facilitated by the study of animals with mutations in the orthologous genes. These are not just animal models, but true orthologues of the humangenetic disease, with defects involving the same evolutionarily conserved genes and the same molecular, biochemical, and anatomic lesions as in humanpatients. These animals are often domestic species because of the individual medical attention paid to them, particularly dogs and cats. In addition, naturally occurring mouse models have also been found in breeding colonies. Within the last several decades, advances in molecular biology have allowed the production of knockout mouse models of humangenetic disease, including the lysosomal storage diseases. The ability to use both inbred strains of a small, prolific species together with larger out-bred animals found because of their disease phenotype provides a powerful combination with which to investigate pathogenesis, develop approaches to therapy, and define biomarkers to evaluate therapeutic success. This has been true for the inborn errors of metabolism and, in particular, the mucopolysaccharidoses. CONCLUSION: Animal models of humangenetic disease continue to play an important role in understanding the molecular and physiological consequences of lysosomal storage diseases and to provide an opportunity to evaluate the efficacy and safety of therapeutic interventions.
Authors: E D Kakkis; E Schuchman; X He; Q Wan; S Kania; S Wiemelt; C W Hasson; T O'Malley; M A Weil; G A Aguirre; D E Brown; M E Haskins Journal: Mol Genet Metab Date: 2001-03 Impact factor: 4.797
Authors: Paul Harmatz; David Ketteridge; Roberto Giugliani; Natalie Guffon; Elisa Leão Teles; M Clara Sá Miranda; Zi-Fan Yu; Stuart J Swiedler; John J Hopwood Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: E D Kakkis; M F McEntee; A Schmidtchen; E F Neufeld; D A Ward; R E Gompf; S Kania; C Bedolla; S L Chien; R M Shull Journal: Biochem Mol Med Date: 1996-08
Authors: Sun H Peck; Philip J M O'Donnell; Jennifer L Kang; Neil R Malhotra; George R Dodge; Maurizio Pacifici; Eileen M Shore; Mark E Haskins; Lachlan J Smith Journal: Mol Genet Metab Date: 2015-09-26 Impact factor: 4.797
Authors: Fritz W Lischka; George Gomez; Karen K Yee; Luba Dankulich-Nagrudny; Leen Lo; Mark E Haskins; Nancy E Rawson Journal: J Comp Neurol Date: 2008-11-20 Impact factor: 3.215
Authors: Seiche C Genger; Keijiro Mizukami; Michael P Martin; Jeffrey R Applegate; H John Barnes; Urs Giger Journal: Avian Pathol Date: 2017-10-10 Impact factor: 3.378
Authors: Daniel J Rowan; Shunji Tomatsu; Jeffrey H Grubb; Adriana M Montaño; William S Sly Journal: J Inherit Metab Dis Date: 2012-09-13 Impact factor: 4.982
Authors: Aaron C Petrey; Heather Flanagan-Steet; Steven Johnson; Xiang Fan; Mitche De la Rosa; Mark E Haskins; Alison V Nairn; Kelley W Moremen; Richard Steet Journal: Dis Model Mech Date: 2011-11-01 Impact factor: 5.758